Government to stock Private Pharmacies with Anti-HIV Drug
“We have seen that people can successfully pick their ARVs from these private pharmacies. So, we think it will be the same with PrEP options,” Kadama said. Read more >>>>>
Category Blog
Your blog category
A New Dawn: World anticipates Gilead’s Lenacapavir Rollout
Uganda is poised to adopt Lenacapavir, a groundbreaking HIV prevention method, following promising results from Gilead Sciences’ PURPOSE 1 trial. The trial, conducted in Uganda and South Africa, demonstrated 100% effectiveness in preventing HIV transmission among women and adolescent girls.…
Injectable HIV drug trial returns promising results
Lenacapavir, which is administered twice yearly, was subjected to a phase three trial in which 5,300 girls and young women aged 16-25 in Uganda and South Africa participated Read more >>>>>>>>>>>>>>>
Ugandan scientists welcome twice-yearly injection against HIV
After over a decade of working on HIV PrEP trials, it’s extremely fulfilling to get such amazing results from the PURPOSE1 study,” said Dr Flavia Matovu Kiweewa. Read more >>>>>>
HIV Prevention breakthrough sparks calls for affordability
First Ugandan Injected with HIV Prevention Drug as General Roll out Starts
The Health Ministry has announced the administration of the first dose of the HIV prevention drug Cabotegravir (Cab-LA) as part of the country’s rollout of long-acting HIV prevention options. Read more >>>>
Purpose 1 Study: First Phase 3 HIV Prevention Trail to Show Zero Infections
Twice-Yearly Lenacapavir or Daily Oral Emtricitabine/Tenofovir Alafenamide for HIV Prevention in Cisgender Women: Interim Analysis Results from the PURPOSE 1 Study Read more >>>>https://www.busogahealthforum.org/download/purpose-1-study-first-phase-3-hiv-prevention-trail-to-show-zero-infections/?wpdmdl=2889&refresh=67307eb1d4b1c1731231409